Trial Profile
A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) Versus Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen for Newly Diagnosed Primary Triple-Negative Inflammatory Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Carcinoma; Early breast cancer; Inflammatory breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 19 Sep 2023 Planned End Date changed from 31 Oct 2023 to 31 Oct 2025.
- 19 Sep 2023 Planned primary completion date changed from 31 Oct 2023 to 31 Oct 2025.
- 12 Sep 2023 Planned End Date changed from 31 Oct 2024 to 31 Oct 2023.